Company profile
MBX Biosciences, Inc.
NASDAQ:MBXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Canvuparatide | phase2 | — | 3 | no active trials |
| Imapextide | phase2 | — | 2 | no active trials |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (8)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07142707 | phase1 | recruiting | 2025-09-03 | 2026-10-30 | MBX Biosciences | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MBX 4291 in Adult Participants With Obesity |
| NCT07699471 | phase3 | recruiting | 2026-08-01 | 2028-01-01 | MBX Biosciences | A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism |
| NCT06531941 | phase2 | active_not_recruiting | 2024-10-31 | 2027-05-27 | MBX Biosciences | Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism |
| NCT06496217 | phase1 | completed | 2024-06-13 | 2025-09-04 | MBX Biosciences | Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function |
| NCT06465108 | phase2 | completed | 2024-08-08 | 2025-05-23 | MBX Biosciences | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism |
FDA applications (0)
No records yet.